In anticipation of the new pharmacovigilance legislation the Medicines Evaluation Board (MEB) decided to simplify the electronic handling of suspected adverse drug reaction reports requiring expedited reporting according to Regulation (EC) No 726/2004 and Directive 2001/83/EC as amended. Marketing Authorisation Holders (MAHs) no longer need to send these reports to the MEB, but should instead [...]